Vizsgálati helyszín
Yuncheng Central Hospital
Yuncheng, Shanxi 044099, KínaMég nincs intézményhez kötve
- 18futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 23 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis19 vizsgálat
- 2. fázis3 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Még nem toboroz6 vizsgálat
- Lezárult5 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Fő szponzor
- Boehringer Ingelheim2 vizsgálat
- Capital Medical University2 vizsgálat
- Shenzhen HighTide Biopharmaceutical Ltd.2 vizsgálat
- Amgen1 vizsgálat
- Beijing 302 Hospital1 vizsgálat
- és még 15
Futó vizsgálatok
Toboroz
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459· 3. fázis· InSilico Medicine Hong Kong Limited· Forrás
Contact: Qinhan Chen
Még nem toboroz
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Lijun Chang, Master of medicine
Toboroz
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186· 3. fázis· Tasly Pharmaceutical Group Co., Ltd· Forrás
Contact: Yanling Qu
Toboroz
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645· 3. fázis· Capital Medical University· Forrás
Contact: Bin Wang
Toboroz
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Li Jia, Master
Toboroz
Phase II Trial of RC1416 Injection in Asthma
NCT07403487· 2. fázis· Nanjing RegeneCore Biotech Co., Ltd.· Forrás
Contact: Zhang Hai Xia
Fut, nem toboroz
RBD5044 in Chinese Participants With Hypertriglyceridemia
NCT07587788· 2. fázis· Ribotek Biopharmaceuticals (Shandong) Co., Ltd· Forrás
Fut, nem toboroz
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
NCT07230119· 3. fázis· Beijing QL Biopharmaceutical Co.,Ltd· Forrás
Toboroz
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308· 3. fázis· Capital Medical University· Forrás
Contact: Bin Wang
Toboroz
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Xiaoke Hou, Master
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· 3. fázis· Amgen· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Még nem toboroz
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647· Beijing 302 Hospital· Forrás
Contact: Lijun Chang
Toboroz
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· 3. fázis· Cytokinetics· Forrás
Contact: Cytokinetics MD
Toboroz
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860· 3. fázis· Beijing InnoCare Pharma Tech Co., Ltd.· Forrás
Contact: Juanli Fan
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Contact: Xiaoke Hou
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· 3. fázis· Shanghai Henlius Biotech· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek